Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferon.
Huang DQ, Shen L, Phyo WW, Cloherty G, Butler EK, Kuhns MC, McNamara AL, Holzmayer V, Gersch J, Anderson M, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lee YM, Lee GH, Tan PS, Muthiah M, Khine HTW, Lee C, Tay A, Lim SG. Huang DQ, et al. Among authors: gersch j. Antiviral Res. 2024 Apr 17;227:105876. doi: 10.1016/j.antiviral.2024.105876. Online ahead of print. Antiviral Res. 2024. PMID: 38641023
HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
Bazinet M, Anderson M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A. Bazinet M, et al. Among authors: gersch j. Hepatol Commun. 2022 Aug;6(8):1870-1880. doi: 10.1002/hep4.1951. Epub 2022 Apr 2. Hepatol Commun. 2022. PMID: 35368148 Free PMC article.
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients.
Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-Silberstein F, Perno CF, Andreoni M, Svicher V, Sarmati L. Cerva C, et al. Among authors: gersch j. Biomedicines. 2022 Feb 14;10(2):443. doi: 10.3390/biomedicines10020443. Biomedicines. 2022. PMID: 35203653 Free PMC article.
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Bazinet M, Anderson M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A. Bazinet M, et al. Among authors: gersch j. Hepatol Commun. 2021 Nov;5(11):1873-1887. doi: 10.1002/hep4.1767. Epub 2021 Jul 10. Hepatol Commun. 2021. PMID: 34558823 Free PMC article. Clinical Trial.
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, Gersch J, Holzmayer V, Elsner C, Krawczyk A, Kuhns MC, Cloherty G, Dittmer U, Vaillant A. Bazinet M, et al. Among authors: gersch j. Hepatol Commun. 2020 Nov 13;5(2):189-202. doi: 10.1002/hep4.1633. eCollection 2021 Feb. Hepatol Commun. 2020. PMID: 33553968 Free PMC article. Clinical Trial.
Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers.
Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, Teti E, Cerva C, Yu La Rosa K, Brugneti M, Bertoli A, Rossi B, Holzmayer V, Gersch J, Kuhns M, Cloherty G, Ceccherini-Silberstein F, Perno CF, Iannetta M, Andreoni M, Sarmati L, Svicher V. Salpini R, et al. Among authors: gersch j. Microorganisms. 2020 Nov 18;8(11):1819. doi: 10.3390/microorganisms8111819. Microorganisms. 2020. PMID: 33218205 Free PMC article.
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
Lim SG, Phyo WW, Ling JZJ, Cloherty G, Butler EK, Kuhns MC, McNamara AL, Holzmayer V, Gersch J, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lee YM, Lee GH, Tan PS, Huang DQ, Khine HTW, Lee C, Tay A, Chan E. Lim SG, et al. Among authors: gersch j. Aliment Pharmacol Ther. 2021 Jan;53(1):172-182. doi: 10.1111/apt.16149. Epub 2020 Nov 7. Aliment Pharmacol Ther. 2021. PMID: 33159496 Clinical Trial.
20 results